These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22617649)

  • 21. The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats.
    Baslow MH; Kitada K; Suckow RF; Hungund BL; Serikawa T
    Neurochem Res; 2002 May; 27(5):403-6. PubMed ID: 12064356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
    Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
    Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.
    Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Purification and preliminary characterization of brain aspartoacylase.
    Moore RA; Le Coq J; Faehnle CR; Viola RE
    Arch Biochem Biophys; 2003 May; 413(1):1-8. PubMed ID: 12706335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of AAV-2-mediated aspartoacylase gene transfer in the tremor rat model of Canavan disease.
    McPhee SW; Francis J; Janson CG; Serikawa T; Hyland K; Ong EO; Raghavan SS; Freese A; Leone P
    Brain Res Mol Brain Res; 2005 Apr; 135(1-2):112-21. PubMed ID: 15857674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary treatment proposed for Canavan's disease.
    Chen V
    Lancet Neurol; 2005 May; 4(5):273. PubMed ID: 15861552
    [No Abstract]   [Full Text] [Related]  

  • 29. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
    Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
    Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical localization of aspartoacylase in the rat central nervous system.
    Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM
    J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat.
    Wang J; Leone P; Wu G; Francis JS; Li H; Jain MR; Serikawa T; Ledeen RW
    Neurochem Res; 2009 Jan; 34(1):138-48. PubMed ID: 18478328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pathogenesis of, and pharmacological treatment for, Canavan disease.
    Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
    Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic acetate therapy improves phenotype in the tremor rat model of Canavan disease.
    Arun P; Madhavarao CN; Moffett JR; Hamilton K; Grunberg NE; Ariyannur PS; Gahl WA; Anikster Y; Mog S; Hallows WC; Denu JM; Namboodiri AM
    J Inherit Metab Dis; 2010 Jun; 33(3):195-210. PubMed ID: 20464498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A case of Canavan disease: the first biochemically proven case in a Japanese girl.
    Hamaguchi H; Nihei K; Nakamoto N; Ezoe T; Naito H; Hara M; Yokota K; Inoue Y; Matsumoto I
    Brain Dev; 1993; 15(5):367-71. PubMed ID: 8279652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation.
    Baslow MH
    J Mol Neurosci; 2003; 21(3):185-90. PubMed ID: 14645985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology and Treatment of Canavan Disease.
    Pleasure D; Guo F; Chechneva O; Bannerman P; McDonough J; Burns T; Wang Y; Hull V
    Neurochem Res; 2020 Mar; 45(3):561-565. PubMed ID: 30535831
    [No Abstract]   [Full Text] [Related]  

  • 37. Canavan disease: a white matter disorder.
    Kumar S; Mattan NS; de Vellis J
    Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous aspartoacylase expression is responsive to glutamatergic activity in vitro and in vivo.
    Francis JS; Strande L; Pu A; Leone P
    Glia; 2011 Oct; 59(10):1435-46. PubMed ID: 21608034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-acetyl-aspartate metabolism at the interface of cancer, immunity, and neurodegeneration.
    Krause N; Wegner A
    Curr Opin Biotechnol; 2024 Feb; 85():103051. PubMed ID: 38103520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A radiometric assay for aspartoacylase activity in cultured oligodendrocytes.
    Madhavarao CN; Hammer JA; Quarles RH; Namboodiri MA
    Anal Biochem; 2002 Sep; 308(2):314-9. PubMed ID: 12419345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.